Dendritic cell-based immunotherapy
TLDR
What has been learned thus far about human DC biology from clinical studies are discussed, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity are discussed.Abstract:
Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.read more
Citations
More filters
Journal ArticleDOI
Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.
TL;DR: The biological functions of immune cells within TME and their roles in cancer immunotherapy are reviewed, and the perspectives of the basic studies for improving the effectiveness of the clinical use are discussed.
Journal ArticleDOI
Therapeutic Targeting of the Tumor Microenvironment
TL;DR: A comprehensive analysis of the current therapies targeting the tumor microenvironment (TME) is provided in this paper, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectives.
Journal ArticleDOI
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
TL;DR: It is argued that in various contexts next-generation DC vaccines are ready to meet some challenges currently confronting ICIs, thereby raising the need to integrate DC vaccines in future combinatorial immunotherapy regimens.
Journal ArticleDOI
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
TL;DR: The role of the different immune landscapes in CRC and their relationships with defined CRC genetic subtypes are discussed and in which ways CRC cells develop mechanisms to resist ICI are considered.
Journal ArticleDOI
Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source
TL;DR: This review summarized the current knowledge on the application of EVs as DDS from the perspective of different cell origin and weighted the advantages and bottlenecks of EV-based DDS.
References
More filters
Journal ArticleDOI
Plasmacytoid Dendritic Cells: Linking Innate and Adaptive Immunity
TL;DR: Plasmacytoid dendritic cells were initially identified in pathological specimens of reactive or neoplastic lymph nodes, in close association with high endothelial venules (HEVs) and their plasma cell-like appearance was initially identified.
Journal ArticleDOI
Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
Eric R. Lutz,Annie A. Wu,Elaine Bigelow,Rajni Sharma,Guanglan Mo,Kevin C. Soares,Sara Solt,Alvin Dorman,Anthony Wamwea,Allison Yager,Daniel A. Laheru,Christopher L. Wolfgang,Jiang Wang,Ralph H. Hruban,Robert A. Anders,Elizabeth M. Jaffee,Lei Zheng +16 more
TL;DR: Post-GVAX T-cell infiltration and aggregate formation resulted in the upregulation of immunosuppressive regulatory mechanisms, including the PD-1–PD-L1 pathway, suggesting that patients with vaccine-primed PDAC may be better candidates than vaccine-naïve patients for immune checkpoint and other immunomodulatory therapies.
Journal ArticleDOI
Cancer immunotherapy with mRNA-transfected dendritic cells
Eli Gilboa,Johannes Vieweg +1 more
TL;DR: Immunization with mRNA‐transfected DCs is a promising strategy to stimulate potent antitumor immunity and could serve as a foundation for developing effective treatments for cancer.
Journal ArticleDOI
Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans.
TL;DR: The capacity of immature DCs to induce antigen-specific regulatory CD8(+) T cells in humans is shown and it is found that interferon-gamma-producing effectors return by 6 months.
Journal ArticleDOI
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty,Drew A. Torigian,E. Gabriela Chiorean,Babak Saboury,Abass Alavi,Andrea B. Troxel,Weijing Sun,Ursina R. Teitelbaum,Robert H. Vonderheide,Peter J. O'Dwyer +9 more
TL;DR: CP-870,893 in combination with gemcitabine was well-tolerated and associated with antitumor activity in patients with PDA, and changes in FDG uptake detected on PET/CT imaging provide insight into therapeutic benefit.
Related Papers (5)
Dendritic cells and the control of immunity
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more